Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 385.07K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.65M | -1.43M | -1.51M | -2.18M | -4.53M | -2.79M |
| Net Income | -1.62M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.07M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 929.66K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 38.51K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 307.63K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.76M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 302.79K | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 1.78M | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
44 Neutral | AU$8.80M | -1.73 | -322.76% | ― | 88.48% | 51.61% | |
44 Neutral | AU$7.57M | -4.69 | -35.12% | ― | 63.30% | 70.00% | |
42 Neutral | AU$6.33M | -0.01 | 226.76% | ― | -21.84% | 79.99% | |
41 Neutral | AU$6.99M | -1.62 | -44.35% | ― | -18.70% | 20.83% | |
39 Underperform | AU$23.91M | -33.08 | -321.20% | ― | 6.76% | ― |
EVE Health Group Limited Corporate Events
EVE Health Group Limited has applied to the ASX for quotation of 64.7 million new fully paid ordinary shares, with an issue date of March 20, 2026. The move reflects a significant expansion of the company’s quoted capital base, which may influence its liquidity and ownership structure, though the announcement provides no additional context on the use of funds or strategic rationale.
The company’s filing, made on March 23, 2026, formalizes the listing of these securities that were previously flagged to the market in earlier transactional disclosures. Stakeholders will likely assess how the enlarged share count affects valuation metrics and market perceptions once the new securities commence trading.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has outlined a target market determination for several series of options linked to a capital raising placement, including free attaching options for sophisticated investors, similar options for director Stuart Gunzburg, and lead manager options for Red Leaf Securities. The options, exercisable at $0.04 and expiring between April 2028 and April 2029, are unquoted instruments aimed at investors already participating in the placement who are accustomed to speculative health and life sciences investments and seeking long-term exposure to potential capital growth if the company’s business development is successful.
The placement will raise approximately $1.29 million from sophisticated investors and an additional $10,000 from the director placement, with two free options issued for every share subscribed under both tranches. By clearly defining the target market and conditions for these options, the company frames the offer as suitable only for informed, higher-risk investors, reinforcing regulatory compliance while aligning its capital structure and incentive mechanisms with stakeholders directly involved in funding and managing the company’s growth initiatives.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has released a transaction-specific prospectus outlining a capital raising via a placement of 64.7 million shares at $0.02 each, seeking $1.294 million, alongside associated options for placement subscribers and directors. The company will also issue options to the lead manager and shares to a corporate adviser for no cash consideration, with several components of the offer subject to shareholder approval and ASX quotation applications to be lodged within seven days of the prospectus date.
The prospectus, lodged with ASIC on 20 March 2026, covers offers of continuously quoted securities and options under section 713 of the Corporations Act, providing a lower level of disclosure than an IPO document. Distribution of the offer is restricted to investors in Australia and New Zealand, with a Target Market Determination available on the company’s website to guide suitability for potential option investors based on their objectives and financial circumstances.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has updated its proposed securities issue, notifying the ASX of an increase in the size of a planned placement first announced on 13 March 2026. The revised Appendix 3B filing reflects the larger capital raising plan, which may provide additional funding flexibility and could influence the company’s capital structure and market positioning.
The update confirms that the securities will be offered under standard ASX procedures for quotation, with the company committing to lodge final issue details once known. This expanded placement may affect existing shareholders through potential dilution while supporting EVE Health Group’s capacity to finance its operational and strategic initiatives in the health sector.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has secured an additional $400,000 from a cornerstone investor in its latest placement, lifting total funds raised to about $1.3 million at $0.02 per share with free attaching options. The strategic investor brings pharmaceutical development and commercialisation expertise, reinforcing external confidence in EVE’s reformulation strategy and its focus on large global markets estimated at more than US$30 billion.
Proceeds from the placement will be used to advance EVE’s reformulated drug candidates in sexual health and cardiovascular segments, further develop its delivery and solubilisation technologies, and support intellectual property and regulatory activities. The strengthened funding position is expected to help EVE progress licensing or supply partnerships with larger pharmaceutical companies that can provide regulatory, manufacturing and distribution capabilities.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has announced a proposed capital raising via a placement, planning to issue 47,450,000 new ordinary fully paid shares on the ASX. The issuance is scheduled for 19 March 2026, indicating the company’s intention to strengthen its balance sheet and support ongoing corporate or operational initiatives.
Alongside the shares, EVE plans to issue 90,400,000 options exercisable at A$0.04 expiring two years from issue and a further 5,000,000 options at the same exercise price expiring in three years. The large option component signals an effort to incentivise investors and potentially secure future capital inflows, which could dilute existing shareholders but provide funding flexibility if the share price appreciates above the exercise level.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has raised $904,000 via a placement to sophisticated and professional investors at $0.02 per share, with investors receiving free attaching options, to accelerate its reformulated pharmaceutical pipeline. The company is targeting established medicines nearing patent expiry, applying its proprietary drug delivery and solubilisation technologies to improve bioavailability, speed of action and patient convenience in large therapeutic markets.
The funds will be directed toward advancing reformulated candidates in sexual health and cardiovascular therapies, further developing EVE’s underlying delivery technologies and supporting intellectual property and regulatory activities. By focusing on drugs with well-known safety profiles in global markets estimated above US$30 billion annually, EVE aims to create differentiated products that can be commercialised through licensing or supply partnerships, potentially strengthening its industry positioning and opening new commercial channels with larger pharmaceutical players.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has requested a trading halt on its securities on the ASX, effective 11 March 2026, while it considers, plans and executes a capital raising. Trading in EVE shares is expected to resume by the start of normal trading on 13 March 2026 or earlier if the company releases its capital raising announcement, signalling an imminent funding move that could impact its capital structure and shareholder positions.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has completed research and development on several reformulated drug candidates in sexual health and cardiovascular therapy, using its proprietary delivery technologies to improve the performance of existing medicines. The expanded pipeline includes oral spray formulations for erectile dysfunction and premature ejaculation, plus a dual-therapy spray, collectively targeting addressable global markets estimated at more than US$30 billion and creating multiple future licensing opportunities.
The company’s strategy focuses on capitalising on the pharmaceutical patent cliff by redesigning drugs nearing or past patent expiry, offering differentiated formats that can be commercialised via established distribution networks. By prioritising compounds with proven safety records, EVE aims to shorten development timelines and reduce risk, strengthening its industry positioning in reformulated therapies and potentially enhancing treatment options and convenience for patients in large, growing markets.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has appointed specialist sexual health physician and general practitioner Dr Sama Balasubramanian to its Scientific Advisory Board, adding deep expertise in men’s health, sexual medicine, medical education and health governance to its advisory ranks. His background includes leadership roles in professional training and policy, as well as experience in evaluating and developing therapeutics for erectile dysfunction and related conditions.
The appointment comes as EVE rolls out Libbo, its oral dissolving film treatment for erectile dysfunction, and advances a broader sexual and reproductive health pipeline supported by a digital prescribing and fulfilment platform. Management expects the strengthened Scientific Advisory Board to enhance product development, clinical trial design and standards-of-care alignment, potentially supporting the commercial uptake of Libbo and positioning EVE more strongly in large, underserved markets for sexual health therapies.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has launched Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia and activated a dedicated men’s health digital platform, stiffissue.com. The company has partnered with telehealth providers hubMed and TeleDocs Clinic and delivery service Chemist2U to create an end-to-end digital pathway for assessment, prescription and home delivery.
The integrated model marks EVE’s transition from pure manufacturing and distribution into real-world patient access, underpinning scalable national reach and near-term revenue generation in men’s health. By combining proprietary products with digital engagement and clinical networks, EVE aims to reduce stigma and access barriers for erectile dysfunction, strengthen its vertically integrated commercial model and lay the groundwork for expansion into additional therapeutic indications.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has transitioned from development to early commercialisation in the December 2025 quarter, with first patient prescriptions of Dyspro™ under Australian regulatory pathways and completion of the initial commercial manufacturing run of Libbo™, which is now in national distribution and positioned for near-term prescribing via telehealth and pharmacies. The company strengthened its clinical and patient engagement infrastructure through a national telehealth patient support agreement with hubMed, launch of the Reclaim My Cycle education and research platform for women with period pain, appointment of its first Medical Science Liaison to drive prescriber education, and a $1.1 million capital raising to accelerate the rollout and regulatory progression of both flagship products, leaving it with $0.9 million in cash and signaling growing investor confidence in its commercialisation strategy.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has completed the first commercial manufacturing run of Libbo, its oral dissolving film treatment for erectile dysfunction, and delivered inventory to a national distribution partner, moving the product from development into commercial launch. With quality-assured stock now integrated into national warehousing, logistics and fulfilment systems, and telehealth prescribing and pharmacy channels in place, the company is positioned for imminent market entry, advancing its men’s health portfolio and underpinning its broader strategy to build scalable, revenue-generating pharmaceutical offerings in the sizable and growing erectile dysfunction treatment market.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has disclosed a change in the shareholding of director Stuart Gunzburg, who acquired 200,000 ordinary shares in the company on 2 January 2026 via an on‑market trade for a total consideration of A$4,200. Following the transaction, Gunzburg’s direct holding remains at 7,936,508 ordinary shares, while his indirect interests through various associated entities increased to 1,180,555 ordinary shares and 1,000,000 unlisted options, signalling a modest increase in his overall equity exposure and aligning his interests more closely with shareholders, though without indicating any broader strategic shift at the company.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.